pharmaceutical companies manufacturing glp-1 receptor agonist medications Market Size & Share Report, 2032 GLP Agonist Clinical Trial Pipeline

However, a subgroup analysis showed that, in trials performed with subjects with obesity, there was a significant reduction of uterine cancers in the GLP1RA arm (MHOR 0.24, 95% CI [0.06, 0.94], Figure 3), whereas no significant difference was found in trials performed in those with diabetes (MHOR 0.92, 95% CI [0.58, 1.47], Figure 3), although the difference between the two groups did not reach statistical significance ( p = 0.07)

p = 0.06) (Table 2)

Hyperglycemia can thus lead to cognitive decline, neurodegeneration, brain atrophy, and altered brain structure and function [110, 111]

Ozempic can lead to up to 15% body weight loss, whereas metformin leads to a 5-7% reduction

Fitch had a similar experience with a patient who ended up throwing up for days after taking a compounded GLP-1 drug

Several drugs are in advanced clinical trials: In Phase III trials: IBI362 (Innovent/Eli Lilly), CagriSema (Novo Nordisk), Retatrutide (Eli Lilly), and Survodutide (Boehringer Ingelheim)